Please Wait
Applying Filters...
menu
    • menu
    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-03

    Virtual Booth

    An Enquiry

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Alintegimod

    DEVELOPMENTS

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    2D Structure
    Also known as: 7hp349, 1378535-08-0, 7hp-349, Alintegimod [inn], Nx38vst3gu, Schembl6121788
    Molecular Formula
    C28H32N2O6S4
    Molecular Weight
    620.8  g/mol
    InChI Key
    PSBCCRKKPBQYJK-UHFFFAOYSA-N
    FDA UNII
    NX38VST3GU
    Alintegimod is an orally bioavailable, allosteric, small molecule activator of integrin cell adhesion receptors very late antigen-4 (VLA-4; integrin alpha4/beta1) and lymphocyte function-associated antigen-1 (LFA-1; integrin alphaL/beta2), with potential immunomodulatory and antineoplastic activities. Upon oral administration, alintegimod activates VLA-4 and LFA-1 expressed on the surface of leukocytes, thereby promoting the VLA-4- and LFA-1-mediated adhesion of leukocytes to counter-receptors vascular cell adhesion molecule-1 (VCAM-1) and intercellular adhesion molecule 1 (ICAM-1). This may promote VLA-4/VCAM-1- and LFA-1/ICAM-1-mediated cell-cell adhesion between naive T-cells and antigen presenting cells (APCs) and enhance T-cell activation. The enhanced VCAM-1 and ICAM-1 binding by the activated integrins expressed on activated T-cells may also promote intratumoral T-cell accumulation and infiltration. This may lead to enhanced T-cell-mediated killing of tumor cells. Integrins VLA-4 and LFA-1 are cellular adhesion molecules (CAMs) that play key roles in antigen presentation and leukocyte migration.
    1 2D Structure

    2D Structure

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    2-[2-[2-[bis(thiophen-2-ylmethyl)carbamoyloxy]ethoxy]ethoxy]ethyl N,N-bis(thiophen-2-ylmethyl)carbamate
    2.1.2 InChI
    InChI=1S/C28H32N2O6S4/c31-27(29(19-23-5-1-15-37-23)20-24-6-2-16-38-24)35-13-11-33-9-10-34-12-14-36-28(32)30(21-25-7-3-17-39-25)22-26-8-4-18-40-26/h1-8,15-18H,9-14,19-22H2
    2.1.3 InChI Key
    PSBCCRKKPBQYJK-UHFFFAOYSA-N
    2.2 Other Identifiers
    2.2.1 UNII
    NX38VST3GU
    2.3 Synonyms
    2.3.1 Depositor-Supplied Synonyms

    1. 7hp349

    2. 1378535-08-0

    3. 7hp-349

    4. Alintegimod [inn]

    5. Nx38vst3gu

    6. Schembl6121788

    7. Chembl5314453

    8. Glxc-26813

    9. Da-70694

    10. Ms-30785

    11. Hy-152832

    12. Cs-0641065

    13. [ethane-1,2-diylbis(oxyethane-2,1-diyl)]bis{bis[(thiophen-2-yl)methyl]carbamate}

    14. C,c'-[1,2-ethanediylbis(oxy-2,1-ethanediyl)] Bis[n,n-bis(2-thienylmethyl)carbamate]

    15. Carbamic Acid, N,n-bis(2-thienylmethyl)-, C,c'-[1,2-ethanediylbis(oxy-2,1-ethanediyl)] Ester

    2.4 Create Date
    2012-12-01
    3 Chemical and Physical Properties
    Molecular Weight 620.8 g/mol
    Molecular Formula C28H32N2O6S4
    XLogP34.6
    Hydrogen Bond Donor Count0
    Hydrogen Bond Acceptor Count10
    Rotatable Bond Count19
    Exact Mass g/mol
    Monoisotopic Mass g/mol
    Topological Polar Surface Area191
    Heavy Atom Count40
    Formal Charge0
    Complexity658
    Isotope Atom Count0
    Defined Atom Stereocenter Count0
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1